miroprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(imidazo[1,2-a]pyridin-2-yl)phenyl group. A non-steroidal anti-inflammatory drug that also exhibits analgesic, antipyretic and platelet aggregation inhibition properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 68752 |
| CHEMBL ID | 2106551 |
| CHEBI ID | 76249 |
| SCHEMBL ID | 26767 |
| MeSH ID | M0069160 |
| Synonym |
|---|
| y-9213 , |
| miroprofen |
| propionic acid, 2-(4-(imidazo(1,2-a)pyridin-2-yl)phenyl)- |
| miroprofene [inn-french] |
| miroprofen [inn] |
| p-imidazo(1,2-a)pyridin-2-ylhydratropic acid |
| y 9213 |
| benzeneacetic acid, 4-imidazo(1,2-a)pyridin-2-yl-alpha-methyl- |
| miroprofeno [inn-spanish] |
| 2-(4-(imidazo(1,2-a)pyridin-2-yl)phenyl)propionic acid |
| brn 0888858 |
| 2-(p-(2-imidazo(1,2-a)pyridiyl)phenyl)propionsaeure [german] |
| miroprofenum [inn-latin] |
| antopen |
| 2-(p-(2-imidazo(1,2-a)pyridyl)phenyl)propionic acid |
| 1-methoxy-3-(2-nitro-1-imidazolyl)-2-propanol |
| propionic acid, 2-(p-(imidazo(1,2-a)pyridin-2-yl)phenyl)- |
| 55843-86-2 |
| 4-imidazo(1,2-a)pyridin-2-yl-alpha-methylbenzeneacetic acid |
| 2-(4-imidazo[1,2-a]pyridin-2-ylphenyl)propanoic acid |
| miroprofenum |
| miroprofene |
| miroprofeno |
| s00i5xg484 , |
| 2-(p-(2-imidazo(1,2-a)pyridiyl)phenyl)propionsaeure |
| unii-s00i5xg484 |
| 2-[4-(imidazo[1,2-a]pyridin-2-yl)phenyl]propanoic acid |
| chebi:76249 , |
| CHEMBL2106551 |
| miroprofen [jan] |
| SCHEMBL26767 |
| 2-[4-(imidazo[1,2-a]pyridin-2-yl)phenyl]propionic acid |
| OJGQFYYLKNCIJD-UHFFFAOYSA-N |
| 2-[p-(2-imidazo[1,2-a]pyridyl)phenyl]propionic acid |
| bdbm50486822 |
| Q3858912 |
| y 0213; y 9213 |
| 2-(4-(IMIDAZO[1,2-A]PYRIDIN-2-YL)PHENYL)PROPANOIC ACID |
| DTXSID30866515 |
| AKOS040753062 |
| Role | Description |
|---|---|
| non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
| antipyretic | A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever. |
| non-narcotic analgesic | A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
| platelet aggregation inhibitor | A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| imidazopyridine | |
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||